Accipiter Biosciences has emerged from stealth with $12.7 million in seed funding to advance a new class of de novo multifunctional protein therapeutics designed to treat complex diseases. The seed ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Hosted on MSN
Seattle startup Accipiter Bio emerges with $12.7M and big pharma deals for AI-designed proteins
A Seattle biotech startup born from a Nobel laureate’s lab has landed $12.7 million and partnerships with pharmaceutical giants Pfizer and Kite Pharma by using AI to design proteins that mount a multi ...
Chronicling the Seattle and Pacific Northwest startup scene. SEE MORE by Lisa Stiffler on Jul 31, 2026 at 9:15 am August 4, 2026 at 11:26 am An illustration of a protein created by Accipiter Bio that ...
The merger between Japan’s MCAP and Ireland’s Accipiter has resulted in the launch of AMCK Aviation today. The merger between Japan’s MCAP and Ireland’s Accipiter has resulted in the launch of AMCK ...
SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Accipiter Biosciences (“Accipiter Bio”), a biotechnology company developing de novo multifunctional biologics to treat complex diseases, today emerged from ...
An illustration of a protein created by Accipiter Bio that has two active sites, shown in light and darker green, that can simultaneously bind two targets. (Accipiter Bio Image) A Seattle biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results